Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
New high-throughput, no-wash assays contribute to the development, manufacture and quality control of safer, more effective biotherapeutics
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
Companies to leverage proprietary IgM antibody technology platform to discover agonists against three oncology targets and three immunology/inflammation targets
Data published in the prestigious journal ACS Central Science of the American Chemical Society
Sputnik Light is the first component of Sputnik V
Inconsistent antibody performance is a significant challenge for researchers and sits at the heart of the reproducibility crisis observed in biomedical research
mRNA-based therapies involve the administration of mRNA in patients so that patients' own cells can produce the encoded therapeutic antibody
Jointly fund and develop up to three antibody-drug conjugate programs for the treatment of cancer
Subscribe To Our Newsletter & Stay Updated
